CDKN2A and neoplasm: CDKN2A mutations were more frequent in non-smokers (Non-smokers: 27/86 vs. Smokers: 15/90, p = 0.033) and NSND patients (NSND: 21/59 vs. SD: 21/117, p = 0.014) and associated with advanced tumour stage (T3/4: 26/71 vs. T1/2: 16/105, p = 0.002) and extracapsular spread (ECS+: 9/20 vs. ECS-: 33/156, p = 0.026).